Publications

Review select publications related to our three translational research projects and the Biospecimen and Pathology Core.

Project 1: Developing a Diagnostic Test and Therapeutic Agents for Fibrolamellar Hepatocellular Carcinoma

2024

Increased protein kinase A activity induces fibrolamellar hepatocellular carcinoma features independent of DNAJB1

Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma

GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma

2023

Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma

Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma

Oncogenic addiction of Fibrolamellar hepatocellular carcinoma to the fusion kinase DNAJB1-PRKACA

Alternative lengthening of telomeres in primary hepatic neoplasms

2022

Clinical and demographic predictors of survival for fibrolamellar carcinoma patients-A patient community, registry-based study

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma

Human liver organoids for disease modeling of fibrolamellar carcinoma

2021

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient¬Derived Xenografts and Direct-from-Patient Screening

Morphologic and Molecular Findings in Myxoid Hepatic Adenomas

Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A

2020

Structural analyses of the PKA Rllf3 holoenzyme containing the oncogenic DnaJB1-PKAc fusion protein reveal protomer asymmetry and fusion-induced allosteric perturbations in fibrolamellar hepatocellular carcinoma

Stem cell-derived polarized hepatocytes

A Human Organoid Model of Aggressive Hepatoblastoma for Disease Modeling and Drug Testing

2019

Structures of the PKA Ria Holoenzyme with the FLHCC Driver J-PKAca or Wild-Type PKAca

2018

Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion

Sequencing the peripheral blood B and T cell repertoire - Quantifying robustness and limitations

Non coding RNA analysis in fibrolamellar hepatocellular carcinoma

Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms

Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma

Intracranial metastasis in fibrolamellar hepatocellular carcinoma

Project 2: Therapeutic Inhibition of Fibroblast Growth Factor and YAP Signaling in Cholangiocarcinoma

2024

Metabolomics Utilized by Machine Learning Approaches Can Classify Cholangiocarcinoma Patients from Normal Controls JHEP Reports [under revision-publication pending]

YAPTEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape Mol Oncology [submitted-publication pending]

2023

LCK inhibtion downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

2022

Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy

2021

FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

2020

The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies

The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma

2019

YAP and the Hippo pathway in cholangiocarcinoma

Project 3: Development of a New Viral Immunotherapeutic Approach for Hepatocellular Carcinoma

2023

Oncolytic viruses: Narcissistic or altruistic arsonists?

Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses

2022

Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

2021

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy

APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable

Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?

Oncolytic virotherapy as immunotherapy

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome

2020

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers

Biospecimen and Pathology Core

2024

Genome-wide DNA methylation markers associated with metabolic liver cancer

Fuel groundbreaking medical research!

Your donation powers the future of medicine and helps save lives.